<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170882</url>
  </required_header>
  <id_info>
    <org_study_id>C16029</org_study_id>
    <secondary_id>2016-004742-28</secondary_id>
    <secondary_id>U1111-1188-2677</secondary_id>
    <secondary_id>2017/1235</secondary_id>
    <secondary_id>N-20170083</secondary_id>
    <secondary_id>17/NW/0546</secondary_id>
    <nct_id>NCT03170882</nct_id>
  </id_info>
  <brief_title>An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of ixazomib+dexamethasone (ixa+dex) versus
      pomalidomide+dexamethasone (pom+dex) on progression-free survival (PFS) in participants with
      relapsed and/or refractory multiple myeloma (RRMM) who have received at least 2 prior lines
      of therapy, including lenalidomide and a proteasome inhibitor, and are refractory to
      lenalidomide but not refractory to proteasome inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat
      people who have relapsed and/or refractory multiple myeloma (RRMM). This study will compare
      the efficacy and safety in participants who take ixazomib and dexamethasone to pomalidomide
      and dexamethasone. It is an open-label, phase 2 study that, on the basis of a prespecified
      go/no-go decision rule, will progress to a phase 3 registrational study.

      The study will enroll approximately 300 patients. Participants will receive:

        -  Ixazomib 4 mg + dexamethasone 20 mg (or 10 mg if participant is aged ≥75 years) OR

        -  pomalidomide 4 mg + dexamethasone 40 mg (or 20 mg if participant is aged ≥75 years)

      All participants will be asked to take either ixazomib plus dexamethasone (in cases where
      only 4 mg tablets for dexamethasone are available, the following dexamethasone schedule is
      recommended for participants aged ≥75 years: 12 mg dexamethasone will be given on Days 1, 8,
      15, and 22 of every 28-day cycle; and 8 mg dexamethasone will be given on Days 2, 9, 16, and
      23 of every 28-day cycle) or pomalidomide 4 mg + dexamethasone 40 mg at recommended doses.

      This multi-center trial will be conducted world wide. The overall time to participate in this
      study is approximately 63 months if the phase 3 portion of the study is completed.
      Alternatively, if the no-go criteria are met during the phase 2 portion, the study will be
      completed approximately 22 to 29 months after the first participant enters the study.

      Participants will make multiple visits to the clinic, and will be contacted for progression
      free survival follow-up, in case of study drug discontinuation for up to 7 years from first
      dose administration. After disease progression, participants will be followed-up for overall
      survival every 12 weeks until death or up to 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until disease progression or death due to any cause, whichever occurs first (Up to 7 years)</time_frame>
    <description>PFS is defined as time from randomization to first documentation of progressive disease (PD) based on central laboratory results and assessment by an independent review committee (IRC) using modified International Myeloma Working Group (IMWG) response criteria or death due to any cause, whichever occurs first. PD requires following:Increase of ≥25% from nadir in:Serum M-component (increase must be ≥0.5 g/dl);Urine M-component (increase must be ≥200 mg/24-hour);In participants without measurable serum and urine M-protein levels difference between involved and uninvolved free light chain (FLC) levels increase of &gt;10 mg/dl;In participants without measurable serum and urine M protein levels and without measurable disease by FLC level:bone marrow plasma cell percentage must be ≥10%;Development of new/ increase in size of existing bone lesions/ soft tissue plasmacytomas;development of hypercalcemia (&gt;11.5 mg/dL corrected serum calcium) attributed solely to plasma cell proliferative disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization up to 10 years</time_frame>
    <description>OS is defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response Rate (ORR - Partial Response [PR], Very Good Partial Response [VGPR] and Complete Response [CR])</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until disease progression for up to 7 years</time_frame>
    <description>ORR is based on laboratory results and independent review committee (IRC) assessment using modified IMWG criteria. PR: ≥50% reduction of serum M protein + reduction in 24-hour urinary M protein by ≥90% or to &lt;200 mg/24-hour; if M protein is not measurable, ≥50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, ≥50% reduction in bone marrow plasma cells, when baseline value = ≥30% and; if present at baseline, ≥50% reduction in size of soft tissue plasmacytomas is required; VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein + urine M-protein level &lt;100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; &lt;5% plasma cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until disease progression for up to 7 years</time_frame>
    <description>DOR is defined as time from first documentation of CR/PR/VGPR to first documentation of PD. Per IMWG criteria, PR:≥50% reduction of serum M protein+reduction in 24-hour urinary M protein by ≥90%/ to &lt;200 mg/24-hour or ≥50% decrease in difference between involved and uninvolved FLC levels/ ≥50% reduction in bone marrow plasma cells, if ≥30% at baseline/ ≥50% reduction in size of soft tissue plasmacytomas. VGPR:serum+urine M-protein detectable by immunofixation but not on electrophoresis/ ≥90% reduction in serum M-protein+urine M-protein level &lt;100 mg/24-hour. CR:negative immunofixation on serum+urine+disappearance of soft tissue plasmacytomas+&lt;5% plasma cells in bone marrow. PD:serum M-component increase ≥0.5 g/dl or urine M-component increase ≥200 mg/24-hour/ difference between involved and uninvolved FLC levels increase &gt;10 mg/dl or bone marrow plasma cell ≥10%/ development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until the first documentation of PR or PR/VGPR/CR for up to 7 years</time_frame>
    <description>Time to response is defined as the time from randomization to the first documentation of PR/VGPR/CR. Per IMWG criteria PR is defined as ≥50% reduction of serum M protein + reduction in 24-hour urinary M protein by ≥90% or to &lt;200 mg/24-hour; if M-protein is not measurable, ≥50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, ≥50% reduction in bone marrow plasma cells, when baseline value = ≥30% and; if present at baseline, ≥50% reduction in size of soft tissue plasmacytomas is required; VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein + urine M-protein level &lt;100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; &lt;5% plasma cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until disease progression for up to 7 years</time_frame>
    <description>TTP is defined as the time from randomization to first documentation of PD. Per IMWG criteria, PD requires 1 of the following: Increase of ≥25% from nadir in: Serum M-component (increase must be ≥0.5 g/dl; Urine M-component (increase must be ≥200 mg/24-hour); In participants without measurable serum and urine M-protein levels difference between involved and uninvolved FLC levels increase of &gt;10 mg/dl; In participants without measurable serum and urine M protein levels and without measurable disease by FLC level: Bone marrow plasma cell percentage must be ≥10%; Development of new or increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (&gt;11.5 mg/dL corrected serum calcium) attributed solely to plasma cell proliferative disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQOL) based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Physical Domain Score</measure>
    <time_frame>Baseline up to 7 years</time_frame>
    <description>The EORTC QLQ-C30 physical domain consists of 5 items covering participant's daily physical activities. The total score reported is between 0 and 100, with a high score indicating better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL based on EORTC QLQ-C30 Total Score</measure>
    <time_frame>Baseline up to 7 years</time_frame>
    <description>The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Score</measure>
    <time_frame>Baseline up to 7 years</time_frame>
    <description>The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. For the body image scale, higher scores = better body image. Higher score for the disease symptoms scale = higher level of symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL based on 5-level Classification System of the EuroQol 5-Dimensional Health Questionnaire (EQ-5D-5L) Score</measure>
    <time_frame>Baseline up to 7 years</time_frame>
    <description>The EQ-5D-5L consists of 2 domains: the EQ-5D-5L descriptive system and the EuroQol visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on 5 levels. 1 = no problems, 2 = slight problems, 3= moderate problems, 4= severe problems, 5 = extremely severe problems. The EQ VAS records the respondent's self-rated health on a 20 cm, vertical, visual analogue scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores from all dimensions are combined into a single index score that is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization (HU): Number of Medical Encounters</measure>
    <time_frame>Baseline up to 7 years</time_frame>
    <description>HU as measured by the number of medical encounters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HU: Duration of Medical Encounters</measure>
    <time_frame>Baseline up to 7 years</time_frame>
    <description>HU as measured by the duration of medical encounters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Relapsed and/or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ixazomib plus dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib 4 mg as starting dose, capsules, orally on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at Cycle 2 for participants who tolerate the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged ≥75 years) tablets, orally, on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (up to 63 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pomalidomide 4 mg, capsules, orally on Days 1 to 21 of each 28-day cycle plus dexamethasone 40 mg, (or 20 mg if participant is aged ≥75 years), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (up to 63 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Ixazomib capsules</description>
    <arm_group_label>Ixazomib plus dexamethasone</arm_group_label>
    <other_name>NINLARO</other_name>
    <other_name>MLN9708</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide capsules</description>
    <arm_group_label>Pomalidomide plus dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone tablets</description>
    <arm_group_label>Ixazomib plus dexamethasone</arm_group_label>
    <arm_group_label>Pomalidomide plus dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have a confirmed diagnosis of multiple myeloma (MM) requiring therapy according
             to International Myeloma Working Group (IMWG) criteria.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          3. Must have had a relapse or progressive disease (PD) after having received 2 or more
             prior lines of systemic therapy. Note: A line of therapy is defined as 1 or more
             cycles of a planned treatment program; this may consist of 1 or more planned cycles of
             single-agent therapy or combination therapy, as well as a sequence of treatments
             administered in a planned manner. For example, a planned treatment approach of
             induction therapy followed by autologous stem cell transplantation (SCT), followed by
             maintenance is considered 1 line of therapy. Typically each line of therapy is
             separated by PD.

          4. Must be refractory to lenalidomide, defined as having received at least 2 consecutive
             cycles of lenalidomide as a single agent or within a lenalidomide-containing regimen
             and having had PD during treatment with or within 60 days after the last dose of
             lenalidomide. The starting dose of lenalidomide should have been 25 mg (or as low as
             10 mg in the case of renal function impairment or other safety concern), and the final
             dose should have been a minimum of 10 mg.

          5. Must have received at least 2 consecutive cycles of a bortezomib- or
             carfilzomib-containing regimen, and either:

               -  Achieved at least a partial response (PR) and did not have PD during treatment
                  with or within 60 days after the last dose of bortezomib or carfilzomib, OR

               -  Had bortezomib and/or carfilzomib intolerance (defined as discontinuation because
                  of drug-related adverse events (AEs) before completion of the planned treatment
                  course) without PD before the start of the next regimen.

          6. Must have measurable disease defined by:

               -  Serum M-protein ≥1 g/dL (≥10 g/L), OR

               -  Urine M-protein ≥200 mg/24 hours and must have documented MM isotype by
                  immunofixation (central laboratory).

          7. Suitable venous access for the study-required blood sampling, including
             pharmacokinetic (PK) sampling.

          8. Recovered (i.e., ≤Grade 1 nonhematologic toxicity) from the reversible effects of
             prior anticancer therapy.

          9. Must be willing and able to adhere to pomalidomide-related risk mitigation activities
             if randomized to the pomalidomide+dexamethasone (pom+dex) arm (e.g., Risk Evaluation
             and Mitigation Strategies [REMS], pregnancy prevention programs).

        Exclusion Criteria:

          1. Prior allogenic bone marrow transplantation in any prior line of therapy or prior
             autologous SCT in the last prior line of therapy.

          2. Diagnosed with or treated for another malignancy within 2 years before randomization,
             or previously diagnosed with another malignancy and have any evidence of residual,
             persistent, or recurrent disease. Participants with nonmelanoma skin cancer or
             carcinoma in situ of any type are not excluded if they have undergone complete
             resection.

          3. Diagnosis of smoldering MM, Waldenström's macroglobulinemia, POEMS (polyneuropathy,
             organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome,
             plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or
             myeloproliferative syndrome.

          4. Peripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of
             any cause on clinical examination during the Screening period.

          5. Treatment with any investigational products or with chimeric or fully human monoclonal
             antibodies within 30 days before randomization, systemic anticancer therapy or
             radiotherapy within 14 days before randomization (Note: &quot;spot&quot; radiation for areas of
             pain is permitted), and major surgery within 14 days before randomization.

          6. Known gastrointestinal disease or gastrointestinal procedure that could interfere with
             the oral absorption or tolerance of study therapy, including difficulty swallowing.

          7. Serious infection requiring parenteral antibiotic therapy or any other serious
             infection within 14 days before randomization.

          8. Central nervous system involvement with MM (by clinical symptoms and signs).

          9. Ongoing or active systemic infection, known human immunodeficiency virus-ribonucleic
             acid (RNA) positive, known hepatitis B surface antigen seropositive, or known
             hepatitis C virus-RNA positive.

         10. Systemic treatment with strong cytochrome P-450 3A inducers (rifampin, rifapentine,
             rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort within
             14 days before randomization.

         11. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-844-622-6468</phone>
    <email>GlobalOncologyMedinfo@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerpen</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ St Jan Brugge Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <state>Kralovehradeck Kraj</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Olomouck Kraj</state>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen Lochotin</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Alborg</city>
        <state>Nordjylland</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne Centre Regional de Lutte Contre Le Cancer</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Dijon Complexe Du Bocage</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Atlantique Vannes</name>
      <address>
        <city>Vannes</city>
        <state>Morbihan</state>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <state>Sarthe</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Havre</name>
      <address>
        <city>Montivilliers</city>
        <state>Seine-Maritime</state>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Fleyriat</name>
      <address>
        <city>Bourg-en- Bresse Cedex</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier (CH) William Morey</name>
      <address>
        <city>Chalon sur Saone</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital d Instructions des Armees Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard Clinique Victor Hugo</name>
      <address>
        <city>Le Mans cedex 2</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional d'Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Perigueux</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Poitiers La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Rennes</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uberortliche Gemeinschaftspraxis Pasing und Furstenfeldbruck</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelismos General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Theageneio Anticancer Oncology Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Centre</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>Emilia-Romagna</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <state>Emilia-Romagna</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cardinale G Panico</name>
      <address>
        <city>Tricase</city>
        <state>Lecce</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <state>Marche</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per lOncologia (IRCCS)</name>
      <address>
        <city>Candiolo</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera S Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Piemonte</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico Regionale A Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>9121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Modena Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Oncologico Della Basilicata</name>
      <address>
        <city>Rionero In Vulture (PZ)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 6 Vicenza</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Sittard</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF Rikshospitalet</name>
      <address>
        <city>Gjettum</city>
        <state>Oppland</state>
        <zip>N-1346</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forde Sentralsjukehus</name>
      <address>
        <city>Forde</city>
        <zip>6812</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Haematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific Center</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n a S P Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 40</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University</name>
      <address>
        <city>Samara</city>
        <zip>433021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Communidad Delaware</state>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsingborg Lasarett</name>
      <address>
        <city>Helsingborg</city>
        <state>Skane Lan</state>
        <zip>SE-25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sodra Alvsborgs Sjukhus Boras</name>
      <address>
        <city>Boras</city>
        <zip>SE-50182</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty Gazi Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Cebeci Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erciyes Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke s Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Betsi Cadwaladr University Health Board</name>
      <address>
        <city>Bodelwyddan</city>
        <state>Denbighshire-SirDdinbych</state>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GenesisCare Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX4 6LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

